News Release

PT Bayer Indonesia Mid Plaza I, 12th Floor Jl. Jend. Sudirman Kav. 10-11 Jakarta 10220, Indonesia Tel: (62 21) 570 3661

Bayer Strengthens Its Commitment to Further Invest and Grow in the Indonesian Market
Bayer Indonesia aims to achieve an average business growth of 10% per year until 2016 by continuously rejuvenating its portfolio in each of its business groups

Jakarta, 16 November 2011 Entering its fifth decade in Indonesia, Bayer is strengthening its commitment in the Indonesian market based on a growth strategy to further substantiate its presence in Indonesia, while also maintaining its position as one of the global companies with core competencies in the fields of health care, nutrition, and high-technology materials.

Bayer Indonesia has recorded (January September 2011) total sales of 175 million (Rp, 2.2 trillion). Bayer MaterialScience contributed 45% of the sales, followed by Bayer HealthCare with 35% and Bayer CropScience with 25%. The sales growth was 11.7% compared to the same period in 2010. Until 2016, Bayer Indonesia aims to achieve business growth in average of around 10% each year, and aims to increase its sales up to 400 million (Rp 5.2 trillion).

Bayer Indonesia is currently expanding and increasing its production capacity of its plant at Cimanggis, Bogor, West Java. This expansion and production-capacity increase will establish the Cimanggis plant, as Bayer Indonesias main production base for pharmaceuticals and Over-The-Counter products, which also serves countries in Asia Pacific and Europe.

- 1/4 -

With an investment of 14.8 million (Rp 200 billion), the Cimanggis plant will increase its production capacity from 37 million packs to 47 million packs by 2015. The expansion of the Cimanggis plant is expected to be completed by the first quarter of 2013.

Aside from the expansion and increase of the production capacity of the Cimanggis plant, Bayer Indonesia is now in the process of preparing a number of new products and applications launches through its three business groups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience.

Our aim is to increase the value and benefits of Bayer in Indonesia by investing in our production capacity, including new technologies and applications, and also introducing new innovative products in the country. These business advances are the manifestation of our commitment to grow and develop together with the Indonesian people, said Dr. Thomas-Peter Hausner, President Director of PT Bayer Indonesia and PT Bayer MaterialScience Indonesia, during a press conference on Perspectives on Growth in Asia and Indonesia, held at the Shangri-La Hotel, Jakarta.

Bayer HealthCare Bayer HealthCare is one of the worlds leading, innovative companies in the health care and
medical products industry. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.

The Indonesia health care market continues to be an attractive market for Bayer. Bayer

HealthCare plans further growth by launching new innovative products. Main activities for 2012 will be the launch of Xarelto and 2013 White & Black.

Xarelto (Rivaroxaban) is an oral anticoagulant discovered by Bayer HealthCares Wuppertal laboratory in Germany, which was then jointly developed by Bayer HealthCare and Johnson&Johnson Pharmaceutical R&D, L.L.C. Xarelto usage has been approved in more than 110 countries, and has been launched in 85 countries including Indonesia by Bayer HealthCare for protection against potentially life threatening venous blood clots

- 2/4 -

(Venous Thromboembolism or VTE) in patients following elective total hip and knee replacement. On November 4th, 2011, Xarelto (Rivaroxaban) has also been approved by the United States Food and Drug Administration (FDA) for indication of reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In Indonesia, Xarelto has been submitted to the National Agency of Drug and Food Control (BPOM), for Stroke Prevention in Atrial Fibrillation indication on March 2011.

White & Black, a cough and cold medicine, is a new product development for Bayer Indonesia. This product consists of two different tablets within one blister, white color is for daylight, black is for night. White & Black is in the process of regulatory approval and expected to be launched in 2013.

Bayer CropScience Bayer CropScience holds a leadership position in the fields of crop protection, environmental science and bioscience. Bayer CropScience Indonesia belongs to the leading companies in this market since 2004, especially in the segments of crop protection business.

According to Dr. Hausner, from 2012 to 2015, Bayer CropScience will launch at least two new crop protection products every year enabling the business to out-grow the market. For 2012, Bayer CropSciences business strategy includes the launch of a new insecticide (Movento) and a new herbicide (Laudis), as well as the release of the newest hybrid rice varieties.

Bayer MaterialScience Bayer MaterialScience is one of the world's largest suppliers of high-performance materials. Its innovative development in coatings, adhesives, insulating materials and sealants, polycarbonates and polyurethanes contributes to improving the quality of human life, particularly in the sectors of automotive, construction, electrical and electronic equipment, household, sports and leisure. - 3/4 -

The new applications for state of the art materials and the optimization of production methods have become the focus of Bayer MaterialScience in fulfilling the demands of the market, said Dr. Hausner. With products providing innovative solutions for companies in Indonesia, as well as the application of the newest production methods, Bayer MaterialScience is expected to grow by eight percent per year and thereby out-growing the market.

*******

Bayer: Science For A Better Life Bayer is a global enterprise with core competencies in the fields of health care, nutrition and hightech materials. The companys products and services are designed to benefit people and improve their quality of life. At the same time Bayer creates value through innovation, growth and high earning power. The Group is committed to the principles of sustainable development and to its role as a socially and ethically responsible corporate citizen. Economy, ecology and social responsibility are corporate policy objectives of equal rank. In fiscal 2010, Bayer employed more than 110,000 people and had sales of 35.1 billion. Capital expenditures amounted to 1.6 billion, R&D expenses to 3.1 billion. For more information, go to www.bayer.com.

For more information please contact: Asmara Pusparani, Corporate Communications Manager PT Bayer Indonesia Tel: +62 21 570 3661 or +62 811 860 6292 E-mail: asmara.pusparani@bayer.com

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

- 4/4 -